Comparison Between One-stage Hybrid Ablation and Thoracoscopic Surgical Ablation for Intractable Atrial Fibrillation
NCT ID: NCT03127423
Last Updated: 2023-04-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2016-12-31
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Two-stage Hybrid Ablation or Thoracoscopic Epicardial Ablation for Long-standing Persistent Atrial Fibrillation
NCT03708471
Thoracoscopic Ablation Versus Catheter Ablation in Patients With Atrial Fibrillation
NCT04237389
One Staged Hybrid Approach of Surgical/Catheter Ablation for Persistent Atrial Fibrillation
NCT02968056
Concomitant Hybrid Versus Catheter Ablation for Atrial Fibrillation With Hypertrophic Cardiomyopathy
NCT05610215
Catheter Ablation and Surgical Ablation of Persistent Atrial Fibrillation With Severe Atrial Fibrosis
NCT05153486
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hybrid ablation group
Patients in this group will receive one-stop intervention with totally thoracoscopic surgical ablation and percutaneous catheter ablation.
Hybrid ablation
This intervention includes totally thoracoscopic surgical ablation and percutaneous catheter ablation simultaneously.
Thoracoscopic surgical ablation group
Patients in this group will receive only totally thoracoscopic surgical ablation with Fuwai lesion set.
Thoracoscopic surgical ablation
This intervention only includes totally thoracoscopic surgical ablation without percutaneous catheter ablation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hybrid ablation
This intervention includes totally thoracoscopic surgical ablation and percutaneous catheter ablation simultaneously.
Thoracoscopic surgical ablation
This intervention only includes totally thoracoscopic surgical ablation without percutaneous catheter ablation.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Persistent AF lasting more than 1 year or with a left atrial diameter\>50mm
Exclusion Criteria
* Presence of significant structural heart disease (dilated cardiomyopathy, hypertrophic cardiomyopathy, valvular heart disease, untreated coronary artery disease)
* Left atrial diameter\>60mm
* Previous thoracic or lung operation
* Left atrial thrombosis or left atrial appendage thrombosis
* Chronic obstructive pulmonary disease (COPD) (Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC)\<70%、FEV1\<50% anticipated value)
* Bilateral carotid artery stenosis\>80%
* Refuse to participate in this study
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China National Center for Cardiovascular Diseases
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhe Zheng, MD,PhD
Role: STUDY_CHAIR
Chinese Academy of Medical Sciences, Fuwai Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
China National Center for Cardiovascular Diseases
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-828
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.